bluebird bio (NASDAQ:BLUE) Earns Sell Rating from Analysts at StockNews.com

by · The Cerbat Gem

StockNews.com initiated coverage on shares of bluebird bio (NASDAQ:BLUE – Free Report) in a research note published on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the company. Wells Fargo & Company cut their target price on bluebird bio from $3.00 to $2.00 and set an equal weight rating for the company in a research note on Wednesday, September 25th. JPMorgan Chase & Co. cut bluebird bio from an overweight rating to a neutral rating in a report on Thursday, August 15th. Bank of America reduced their price objective on bluebird bio from $4.00 to $3.00 and set a buy rating on the stock in a research note on Thursday, August 15th. Cantor Fitzgerald reissued a neutral rating on shares of bluebird bio in a research note on Monday, September 16th. Finally, Barclays reduced their price target on shares of bluebird bio from $8.00 to $4.00 and set an overweight rating on the stock in a research note on Thursday, August 15th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of Hold and an average target price of $4.63.

View Our Latest Stock Report on bluebird bio

bluebird bio Price Performance

Shares of NASDAQ:BLUE opened at $0.49 on Friday. The firm has a 50 day moving average of $0.67 and a 200-day moving average of $0.91. bluebird bio has a 12 month low of $0.45 and a 12 month high of $5.53. The company has a current ratio of 0.93, a quick ratio of 0.82 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $53.27 million, a PE ratio of -0.66 and a beta of 0.75.

Hedge Funds Weigh In On bluebird bio

Several large investors have recently modified their holdings of the business. Ghisallo Capital Management LLC acquired a new stake in bluebird bio in the fourth quarter valued at $4,347,000. Pennant Investors LP acquired a new stake in shares of bluebird bio in the fourth quarter valued at about $121,000. Masters Capital Management LLC bought a new position in shares of bluebird bio during the fourth quarter worth about $1,380,000. Virtu Financial LLC acquired a new position in shares of bluebird bio in the fourth quarter worth approximately $317,000. Finally, HBK Investments L P bought a new stake in bluebird bio in the fourth quarter valued at approximately $2,070,000. Institutional investors own 87.43% of the company’s stock.

About bluebird bio

(Get Free Report)

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.

Featured Articles